Novel benzofuran-3-one indole inhibitors of PI3 kinase-α and the mammalian target of rapamycin: Hit to lead studies

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 8, 2010, Pages 2586-2590

  Bursavich, Matthew G ^a   Brooijmans, Natasja ^a   Feldberg, Lawrence ^a   Hollander, Irwin ^a   Kim, Stephen ^a   Lombardi, Sabrina ^a   Park, Kaapjoo ^a   Mallon, Robert ^a   Gilbert, Adam M ^a  

^a WYETH RESEARCH   (United States)

Author keywords

Kinase; Mammalian target of rapamycin; Phosphatidylinositol 3 kinases

Indexed keywords

BENZOFURAN 3 ONE INDOLE DERIVATIVE; BENZOFURAN DERIVATIVE; INDOLE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SELECTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BENZOFURANS; CELL LINE, TUMOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

MAMMALIA;

EID: 77950169471     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.082     Document Type: Article

References (15)

1. Vanhaesebroeck B., Leevers S.J., Ahmadi K., Timms J., Katso R., Driscoll P.C., Woscholski R., Parker P.J., and Waterfield M.D. Annu. Rev. Biochem. 70 (2001) 535
2. Liu P., Cheng H., Roberts T.M., and Zhao J.J. Nat. Rev. Drug Disc. 8 (2009) 627
3. Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J.S., Malmstrom P.O., Mansukhani M., Enoksson J., Hibshoosh H., Borg A., and Parsons R. Cancer Res. 65 (2005) 2554
4. She Q.B., Solit D., Basso A., and Moasser M.M. Clin. Cancer Res. 9 (2003) 4340
5. Wee S., Lengauer C., and Wiederschain D. Curr. Opin. Oncol. 20 (2008) 77
6. Ameriks M.K., and Venable J.D. Curr. Top. Med. Chem. 9 (2009) 738
7. Tsang C.K., Qi H., Liu L.F., and Zheng X.F.S. Drug Discovery Today 12 (2007) 112
8. Gilbert A.M., Nowak P., Brooijmans N., Bursavich M.G., Dehnhardt C., Santos E.D., Feldberg L.R., Hollander I., Kim S., Lombardi S., Park K., Venkatesan A.M., and Mallon R. Bioorg. Med. Chem. Lett. 20 (2010) 636
9. Venkatesan A.M., Dehnhardt C.M., Chen Z., Santos E.D., Dos Santos O., Bursavich M., Gilbert A.M., Ellingboe J.W., Ayral-Kaloustian S., Khafizova G., Brooijmans N., Mallon R., Hollander I., Feldberg L., Lucas J., Yu K., Gibbons J., Abraham R., and Mansour T.S. Bioorg. Med. Chem. Lett. 20 (2010) 653
10. 1H NMR and reversed phases-HPLC/MS spectroscopy.
11. Gastpar R., Goldbrunner M., Marko D., and von Angerer E. J. Med. Chem. 41 (1998) 4965
12. Tanaka M., Kaneko T., Akamatsu H., Okita M., Chiba K., Obaishi H., Sakurai H., and Yamatsu I. Eur. J. Med. Chem. 30 (1995) 179
13. Teo C.C., Kon O.L., Sim K.Y., and Ng S.C. J. Med. Chem. 35 (1992) 1330
14. Yu K., Toral-Barza L., Discafani C., Zhang W.G., Skotnicki J., Frost P., and Gibbons J.J. Endocr. Relat. Cancer 8 (2001) 249
15. de la Mora M.A., Cuevas E., Muchowski J.M., and Cruz-Almanza R. Tetrahedron Lett. 42 (2001) 5351